Earnings Call · Q4 FY2022·2023-02-23

Q4 22EPS +100.00%*·Rev n/aQ3 22EPS +12.87%·Rev n/aQ2 22EPS +5.62%·Rev n/aQ1 22EPS +1.14%·Rev n/a⚠ consensus missing

AGIOS PHARMACEUTICALS, INC. AGIO

Jessi Rennekamp — Investor Relations or Communications

Brian Goff — Chief Executive Officer

Sarah Gheuens — Chief Medical Officer

Tsveta Milanova — Chief Commercial Officer

Cecilia Jones — Chief Financial Officer

−1.7%1d on move date−2.3% vs SPY3d−4.8%5d−5.7%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more AGIO calls or request research access.

More AGIO calls Browse calls Request research access